Earendil Labs vs Relay Therapeutics

Side-by-side comparison of AI visibility scores, market position, and capabilities

Earendil Labs leads in AI visibility (53 vs 35)
Earendil Labs logo

Earendil Labs

ChallengerBioTech

AI Drug Discovery

Full-stack AI biologics company raised $787M in Mar 2026 backed by Sanofi, Pfizer/Hillhouse, and DST Global; $2.56B Sanofi collaboration signed Jan 2026; platform generates 40+ AI-designed protein therapeutics across multiple therapeutic areas.

AI VisibilityBeta
Overall Score
C53
Category Rank
#53 of 198
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
49
Perplexity
49
Gemini
55

About

Earendil Labs is a full-stack AI biologics company that uses a proprietary AI platform to design protein therapeutics at scale. The company secured $787 million in financing in March 2026, backed by Sanofi, the Pfizer-Hillhouse Biotech Fund, Dimension Capital, and DST Global — one of the largest AI drug discovery raises in the industry's history.

Full profile
Relay Therapeutics logo

Relay Therapeutics

EmergingLife Sciences & BioTech

AI Drug Discovery

Cambridge MA precision oncology biotech using Dynamo platform to exploit protein motion for drug design; lead asset RLY-2608 targets PI3Kα in breast cancer.

AI VisibilityBeta
Overall Score
D35
Category Rank
#144 of 198
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
39
Perplexity
41
Gemini
34

About

Relay Therapeutics was founded in 2016 in Cambridge, Massachusetts, emerging from research at MIT and D.E. Shaw Research. The company is built around its Dynamo platform, which integrates computational protein motion modeling (molecular dynamics simulations) with structural biology and medicinal chemistry to design small-molecule drugs that exploit the dynamic conformational states of disease-relevant proteins—a dimension traditional structure-based drug design ignores.\n\nRelay's lead program, RLY-2608, is a first-in-class allosteric, mutant-selective PI3Kα inhibitor for advanced breast cancer patients with PI3KCA mutations. Unlike approved PI3Kα inhibitors that cause metabolic toxicity by inhibiting wild-type PI3Kα in normal tissues, RLY-2608 selectively targets the mutant form. The compound has shown early clinical promise including objective responses in patients who progressed on prior alpelisib, supporting a differentiated profile. Additional programs target FGFR2 and SHP2 in solid tumors.\n\nRelay has raised over $1.2 billion in equity financing and holds substantial cash reserves. The company is conducting multiple clinical trials and building a pipeline that validates its Dynamo-guided discovery approach. Though revenue-stage remains early, Relay represents a leading example of next-generation computational oncology companies seeking to turn protein dynamics insights into selective, differentiated medicines.

Full profile

AI Visibility Head-to-Head

53
Overall Score
35
#53
Category Rank
#144
79
AI Consensus
79
stable
Trend
stable
49
ChatGPT
39
49
Perplexity
41
55
Gemini
34
55
Claude
33
48
Grok
36

Key Details

Category
AI Drug Discovery
AI Drug Discovery
Tier
Challenger
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Earendil Labscompetes withRelay Therapeutics

Capabilities

Shared
AI Drug Discovery

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.